Shares of Bavarian Nordic (OTCMKTS:BVNRY – Get Free Report) gapped down prior to trading on Thursday . The stock had previously closed at $9.58, but opened at $9.0680. Bavarian Nordic shares last traded at $9.0680, with a volume of 140 shares trading hands.
Bavarian Nordic Stock Performance
The firm has a market capitalization of $2.16 billion, a price-to-earnings ratio of 5.85 and a beta of 1.34. The business’s 50-day moving average is $10.16 and its two-hundred day moving average is $10.78.
Bavarian Nordic Company Profile
Bavarian Nordic is a fully integrated biotechnology company specializing in the development, manufacture and commercialization of vaccines and immunotherapies. Founded in 1994 and headquartered in Martinsried, Germany, the company combines internal research capabilities with in-house manufacturing to address serious infectious diseases and cancer indications. Bavarian Nordic’s operations encompass preclinical research, clinical development and commercial supply, with a strategic focus on leveraging its proprietary viral vector platforms.
The company’s commercial portfolio includes approved prophylactic vaccines such as Jynneos™ (marketed as Imvamune®/Imvanex®) for the prevention of smallpox and monkeypox in the United States, European Union and Canada; Rabipur® for rabies prevention; and Encepur® against tick-borne encephalitis.
See Also
- Five stocks we like better than Bavarian Nordic
- The Forbes Mineral America Needs
- How China Accidentally Created Its Own Rare Earth Rival
- Trump’s NEW Executive Order – BIG Changes Coming to Retirement Accounts
- A personal warning from Martin Weiss (Please read)
- Central banks just did something they haven’t done since 1967
Receive News & Ratings for Bavarian Nordic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bavarian Nordic and related companies with MarketBeat.com's FREE daily email newsletter.
